Engineering Strategies for Allogeneic T Cell-Based Platforms in Cancer Immunotherapy

Le résumé fourni par la source

Allogeneic T cell therapies have emerged as a promising strategy to overcome the logistical and manufacturing limitations of autologous approaches, enabling scalable, off-the-shelf cancer immunotherapy. While early clinical efforts have focused predominantly on αβ T cell-based platforms, including CAR- and TCR-engineered approaches, a growing spectrum of alternative cell types, such as γδ T cells, invariant natural killer T cells, mucosal-associated invariant T cells, and induced pluripotent stem cell-derived effectors, is expanding the design landscape of allogeneic therapies. However, clinical translation remains constrained by immune rejection, limited persistence, lymphodepletion-associated toxicity, manufacturing variability, and impaired efficacy in solid tumors. To address these barriers, engineering strategies have increasingly integrated T cell receptor disruption, human leukocyte antigen modulation, cytokine support, checkpoint editing, and synthetic circuit design. This review provides an oncology-focused, cross-platform framework for evaluating diverse allogeneic T cell and T cell-like platforms according to clinical maturity, safety, manufacturability, persistence, and tumor-targeting capacity. We further discuss how platform-specific biological properties and clinical evidence can be integrated with modular engineering strategies to optimize antitumor performance. These insights support a shift from platform-centric development toward a design-driven paradigm for next-generation allogeneic cellular immunotherapies with improved efficacy, safety, and scalability.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.